- Home
- AVTX vs GDO Comparison
AVTX vs GDO Comparison
Compare AVTX & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- GDO
- Stock Information
- Founded
- AVTX 2011
- GDO 2009
- Country
- AVTX United States
- GDO United States
- Employees
- AVTX N/A
- GDO N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- GDO Finance Companies
- Sector
- AVTX Health Care
- GDO Finance
- Exchange
- AVTX Nasdaq
- GDO Nasdaq
- Market Cap
- AVTX 138.8M
- GDO 90.2M
- IPO Year
- AVTX 2015
- GDO N/A
- Fundamental
- Price
- AVTX $10.14
- GDO $12.06
- Analyst Decision
- AVTX Strong Buy
- GDO
- Analyst Count
- AVTX 8
- GDO 0
- Target Price
- AVTX $31.00
- GDO N/A
- AVG Volume (30 Days)
- AVTX 168.1K
- GDO 39.4K
- Earning Date
- AVTX 11-06-2025
- GDO 01-01-0001
- Dividend Yield
- AVTX N/A
- GDO 9.81%
- EPS Growth
- AVTX N/A
- GDO N/A
- EPS
- AVTX N/A
- GDO N/A
- Revenue
- AVTX $441,000.00
- GDO N/A
- Revenue This Year
- AVTX N/A
- GDO N/A
- Revenue Next Year
- AVTX N/A
- GDO N/A
- P/E Ratio
- AVTX N/A
- GDO N/A
- Revenue Growth
- AVTX N/A
- GDO N/A
- 52 Week Low
- AVTX $3.39
- GDO $11.21
- 52 Week High
- AVTX $16.00
- GDO $13.04
- Technical
- Relative Strength Index (RSI)
- AVTX 54.75
- GDO 65.68
- Support Level
- AVTX $8.65
- GDO $11.93
- Resistance Level
- AVTX $12.41
- GDO $12.00
- Average True Range (ATR)
- AVTX 0.92
- GDO 0.08
- MACD
- AVTX -0.08
- GDO 0.00
- Stochastic Oscillator
- AVTX 39.63
- GDO 98.33
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.